Evidence map›Paper›PMID 41279486›Full record

ArticlebioRxiv : the preprint server for biology2025

Elevated Na

Yuma Mizuno, Shiyue Pan, Tong Zhou, Patrick G Kehoe, Yumei Feng Earley

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Yuma MizunoDepartment of Physiology and Cell Biology, University of Nevada, Reno, NV, USA.
Shiyue PanDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Tong ZhouDepartment of Physiology and Cell Biology, University of Nevada, Reno, NV, USA.
Patrick G KehoeCerebrovascular and Dementia Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Yumei Feng EarleyDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Funding

TRP channels as fundamental sensors of the cerebral microcirculationR35HL155008 · NHLBI · UNIVERSITY OF ROCHESTER · PI Scott Earley · 2021 to 2026
$5.5M
The Neural Mechanisms of HypertensionR01HL122770 · NHLBI · UNIVERSITY OF ROCHESTER · PI FENG EARLEY, YUMEI · 2015 to 2023
$4.2M
Neural mechanisms regulating glucose homeostasisR01DK135621 · NIDDK · UNIVERSITY OF ROCHESTER · PI Yumei Feng Earley · 2023 to 2026
$2.2M
NHLBI NIH HHS R01 HL122770NHLBI NIH HHS R35 HL155008NIDDK NIH HHS R01 DK135621
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and the accumulation of amyloid plaques and neurofibrillary tangles. While prior research has focused mainly on protein aggregation and neuroinflammation, emerging evidence suggests that ionic imbalances, particularly involving sodium (Na+) and potassium (K+), may contribute to AD progression. Na+ and K+ are critical for maintaining neuronal membrane potential, regulating action potential firing, and supporting neurotransmitter function. Although studies primarily focused on absolute Na+ concentrations, the Na+/K+ ratio may provide a more sensitive marker of ionic dysregulation. Given that the Na+/K+ gradient is actively maintained by the Na/K-ATPase pump, a target known to be vulnerable in AD, we hypothesized that the Na+/K+ ratio is altered in AD. We analyzed postmortem tissue from the prefrontal cortex, thalamus, and cerebrospinal fluid (CSF) of 97 human subjects (67 AD, 30 controls). AD cases exhibited a significant increase in the Na+/K+ ratio in the thalamus and CSF, driven primarily by elevated Na+ levels. The Na+/K+ ratio positively correlated with Braak tangle stage, suggesting an association with AD progression. These findings provide novel insights into ionic dysregulation in AD and suggest that the CSF Na+/K+ ratio may serve as a valuable biomarker of disease severity and progression. Future research should explore the potential of targeting ionic homeostasis as a therapeutic strategy in AD.

Indexed as

Alzheimer’s Diseasebrain sodiumcerebrospinal fluid sodiumNa+/K+ ratio

Identifiers

PMID41279486
PMCPMC12637545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.